The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps (Apheresis, Separation, Expansion, Harvest, Fill Finish, Cryopreservation and Thawing), Scale of Operations (Preclinical / Clinical and Commercial), End Users (Hospitals / Medical Centers / Clinics / Research Institutes and Commercial Organizations) and Geographical Regions (North America, Europe, Asia Pacific, LATAM and MENA): Industry Trends and Global Forecasts, 2020 - 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    October 2020

  • Pages
    184

  • View Count
    661

Example Insights

Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-Context Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-Different-companies Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-landscape
Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-Product-Competitiveness-Analysis Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-Partnerships-and-Collaborations Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-Big-Pharma-Initiatives
Automated-and-Closed-Cell-Therapy-Processing-Systems-Market-Forecast    

 

Overview

Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies. However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination. Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose. 

Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality. Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.

Scope of the Report

The “Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill / Finish, Cryopreservation, Thawing, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, featuring an elaborate list of over 60 automated and closed systems, along with information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert system), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification / validation, maintenance, regulatory support and others) and regulatory certification / accreditations obtained (GMP / cGMP, GAMP, GCP, GTP / cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).
  • An insightful product competitiveness analysis, taking into consideration various relevant parameters, such as supplier power (based on the experience / expertise of the developer in this industry) and portfolio-related parameters, such as number of systems offered, cells supported, type of culture supported, scale of operation, applications, end users, support services offered, regulatory certifications / accreditations obtained and key product specifications. 
  • Elaborate profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
  • An analysis of the various partnerships pertaining to automated and closed cell therapy processing systems, which have been established since 2016, based on several parameters, such as year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner’s focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.
  • A review of recent initiatives undertaken by big pharma players in automated and closed cell processing systems domain.

One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial organizations), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis)
  • Jean Sebastien Parisse (Commercial Director, Aseptic Technologies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Which are the popular automated and closed systems commonly used for cell therapy processing?
  • Who are the leading industry and non-industry players in this domain?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • Which players are likely to be potential partners of automated and closed system providers?
  • What is the current and likely future cost saving opportunities associated with use of automated and closed systems for cell therapy processing?
  • What are the key trends within the automated and closed cell therapy processing systems market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the automated and closed cell therapy processing systems market and its likely evolution in the short-mid-term and long term.

Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of products. It features a detailed discussion on the key challenges associated with currently adopted cell therapy manufacturing approaches. The chapter also highlights the role of automation in cell therapy manufacturing, providing details on the key advantages and challenges associated with such systems. Further, it features a discussion on the key growth drivers and roadblocks related to the use of such systems, as well as certain trends that the domain is expected to witness in the coming years.

Chapter 4 provides an overview of the automated and closed cell therapy processing systems landscape. It includes information on more than 60 automated and closed systems that are currently being used for processing the cell therapies. It features detailed information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert systems), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification / validation, maintenance, regulatory support and others), regulatory certification / accreditations obtained (GMP / cGMP, GAMP, GCP, GTP / cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).

Chapter 5 presents a detailed competitiveness analysis of automated and closed cell therapy processing systems based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 presents detailed profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

Chapter 7 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, during the period 2016-2020. It provides a brief description on the various types of partnership models adopted (including asset purchase agreement, distribution agreement, joint venture, merger / acquisition,  product commercialization agreement, product development agreement, product development and commercialization agreement, product evaluation agreement, product integration agreement, product utilization agreement, research agreement and others) by stakeholders in this domain. Further, it includes analyses based on the year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner’s focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.

Chapter 8 highlights the recent initiatives undertaken by big pharma players in the automated and closed cell therapy processing systems domain.

Chapter 9 features a list of more than 300 cell therapy developers and manufacturers that are anticipated to partner with automated and closed cell therapy processing system providers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company’s size and its experience in this field), company’s pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), type of culture used (adherent or suspension) and type of technology (automated systems or closed systems).

Chapter 10 presents a case study, highlighting the differences in cost associated with manufacturing of cell therapies using manual, partially automated and bespoke automated and closed systems, across various process operations.

Chapter 11 presents a detailed market forecast analysis, highlighting the likely growth of the automated and closed cell therapy processing systems market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America).

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis), and Jean Sebastien Parisse (Commercial Director, Aseptic Technologies).

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
4.2.1. Analysis by Cell Processing Step
4.2.2. Analysis by Types of Cells 
4.2.3. Analysis by Type of Culture
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Key Features
4.2.6. Analysis by Application Area
4.2.7. Analysis by Regulatory Certifications / Accreditations 
4.2.8. Analysis by End User

4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size 
4.3.3. Analysis by Type of Support Service(s) Offered 
4.3.4. Analysis by Location of Headquarters 

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis
5.4.1. Automated and Closed Cell Processing Systems for Apheresis
5.4.2. Automated and Closed Cell Processing Systems for Separation
5.4.3. Automated and Closed Cell Processing Systems for Expansion
5.4.4. Automated and Closed Cell Processing Systems for Harvest
5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
5.4.7. Automated and Closed Cell Processing Systems for Thawing

6. COMPANY PROFILES
6.1 Chapter Overview
6.2 Cytiva
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Pall
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. Terumo BCT
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook

6.5 ThermoGenesis
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook

7. PARTNERSHIPS
7.1 Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Therapy
7.3.4. Analysis by Cell Processing Step
7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
7.3.6. Analysis by Partner’s Focus Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Country-Wise Distribution
7.3.8.2. Intercontinental and Intracontinental Agreements

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN
8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
8.2.1. Initiatives Undertaken by AbbVie
8.2.2. Initiatives Undertaken by Bristol Myers Squibb
8.2.3. Initiatives Undertaken by Gilead Sciences
8.2.4. Initiatives Undertaken by GlaxoSmithKline
8.2.5. Initiatives Undertaken by Johnson & Johnson
8.2.6. Initiatives Undertaken by Novartis
8.2.7. Initiatives Undertaken by Roche
8.2.8. Initiatives Undertaken by Sanofi
8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
8.2.10. Summary of Big Pharma Initiatives 

9. LIKELY PARTNER
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
9.3.1. Dendritic Cell Therapy
9.3.2. Stem Cell Therapy
9.3.3. T-cell Therapy
9.3.4. Natural Killer Cell Therapy

9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
9.4.1. Dendritic Cell Therapy
9.4.2. Stem Cell Therapy,
9.4.3. T-cell Therapy
9.4.4. Natural Killer Cell Therapy

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS
10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah®
10.4. Likely Cost Saving Potential for Yescarata®
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030

11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, 2020-2030
11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, 2020-2030
11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, 2020-2030
11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, 2020-2030
11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, 2020-2030
11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, 2020-2030
11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, 2020-2030

11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, 2020-2030
11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, 2020-2030

11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030
11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, 2020-2030

11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, 2020-2030
11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, 2020-2030
11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, 2020-2030
11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), 2020-2030
11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), 2020-2030

12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways

13. INTERVIEW / SURVEY TRANSCRIPT(S)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

Figure 3.1. Key Steps Involved in Manufacturing of Cell Therapies
Figure 3.2. Key Considerations while Automating Cell Therapy Manufacturing Process
Figure 3.3. Role of Automated and Closed Systems across Each Cell Therapy Processing Step
Figure 3.4. Advantages offered by Automated and Closed Cell Processing Systems
Figure 3.5. Challenges Associated with Automated and Closed Cell Processing Systems
Figure 3.6. Growth Drivers and Roadblocks in the Automated and Closed Systems Market
Figure 4.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Figure 4.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Figure 4.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Figure 4.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Figure 4.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Figure 4.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Figure 4.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Figure 4.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Figure 4.9. Automated and Closed Cell Therapy Processing System Providers: Distribution by Year of Establishment
Figure 4.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Figure 4.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Figure 4.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Figure 4.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Figure 4.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Figure 5.1. Product Competitiveness Analysis: Automated and Closed Systems for Cell Apheresis
Figure 5.2. Product Competitiveness Analysis: Automated and Closed Systems for Cell Separation
Figure 5.3. Product Competitiveness Analysis: Automated and Closed Systems for Cell Expansion
Figure 5.4. Product Competitiveness Analysis: Automated and Closed Systems for Cell Harvesting
Figure 5.5. Product Competitiveness Analysis: Automated and Closed Systems for Fill Finish
Figure 5.6. Product Competitiveness Analysis: Automated and Closed Systems for Cryopreservation
Figure 5.7. Product Competitiveness Analysis: Automated and Closed Systems for Thawing
Figure 6.1. Terumo BCT: Annual Revenues, FY 2016 – FY 2020
Figure 6.2. ThermoGenesis: Annual Revenues, FY 2016 – FY 2020
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Figure 7.4. Recent Partnerships: Distribution by Type of Therapy
Figure 7.5. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Figure 7.6. Recent Partnerships: Distribution by Cell Processing Step
Figure 7.7. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Figure 7.8. Recent Partnerships: Distribution by Type of Partner
Figure 7.9. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Figure 7.10. Recent Partnerships: Most Active Players
Figure 7.11. Recent Partnerships: Country-Wise Distribution
Figure 7.12. Recent Partnerships: Intercontinental and Intracontinental Distribution
Figure 8.1. Big Pharma Initiatives Summary
Figure 10.1. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
Figure 10.2. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Figure 10.3. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Figure 11.1. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
Figure 11.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
Figure 11.3. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
Figure 11.4. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
Figure 11.5. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
Figure 11.6. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
Figure 11.7. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
Figure 11.8. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
Figure 11.9. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
Figure 11.10. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
Figure 11.11. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Figure 11.12. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
Figure 11.13. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
Figure 11.14. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
Figure 11.16. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
Figure 11.17. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Figure 11.18. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
Figure 11.19. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
Figure 11.20. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
Figure 11.21. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
Figure 11.22. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)

List Of Tables

Table 3.1. Cell and Advanced Therapies: Key Applications
Table 3.2. Assessment of Key Cell Therapy Manufacturing Steps
Table 4.1. List of Automated and Closed Cell Therapy Processing Systems: Information on Cell Processing Step
Table 4.2. List of Automated and Closed Cell Therapy Processing Systems: Information on Types of Cells
Table 4.3. List of Automated and Closed Cell Therapy Processing Systems: Information on Type of Culture
Table 4.4. List of Automated and Closed Cell Therapy Processing Systems: Information on Scale of Operation
Table 4.5. List of Automated and Closed Cell Therapy Processing Systems: Information on Key Features
Table 4.6. List of Automated and Closed Cell Therapy Processing Systems: Information on Application Area
Table 4.7. List of Automated and Closed Cell Therapy Processing Systems: Information on Regulatory Certifications / Accreditations Obtained
Table 4.8. List of Automated and Closed Cell Therapy Processing Systems: Information on End Users
Table 4.9. List of Automated and Closed Cell Therapy Processing System Providers
Table 4.10. List of Automated and Closed Cell Therapy Processing System Providers: Information on Type of Support Service(s) Offered
Table 6.1. Cytiva: Key Highlights
Table 6.2. Cytiva: Product Portfolio
Table 6.3. Pall: Key Highlights
Table 6.4. Pall: Product Portfolio
Table 6.5. Terumo BCT: Key Highlights
Table 6.6. Terumo BCT: Product Portfolio
Table 6.7. Terumo BCT: Recent Developments and Future Outlook
Table 6.8. ThermoGenesis: Key Highlights
Table 6.9. ThermoGenesis: Product Portfolio
Table 6.10. ThermoGenesis: Recent Developments and Future Outlook
Table 7.1. Automated and Closed Cell Processing Systems: List of Partnerships, 2016-2020
Table 8.1. Automated and Closed Cell Processing Systems: List of Big Pharma Players
Table 9.1. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Developers
Table 9.2. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Developers
Table 9.3. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Developers
Table 9.4. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Developers
Table 9.5. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Manufacturers
Table 9.6. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Manufacturers
Table 9.7. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Manufacturers
Table 9.8. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Manufacturers
Table 10.1. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems, 2020-2030
Table 10.2. Cost Saving Potential of Fully Automated Systems
Table 14.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Table 14.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Table 14.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Table 14.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Table 14.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Table 14.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Table 14.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Table 14.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Table 14.9. Automated and Closed Cell Therapy Processing System Providers: Distribution Year of Establishment
Table 14.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Table 14.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Table 14.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Table 14.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Table 14.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Table 14.15. Terumo BCT: Annual Revenues, FY 2016-FY 2020
Table 14.16. ThermoGenesis: Annual Revenues, FY 2016 – FY 2020
Table 14.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 14.18. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Table 14.19. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Table 14.20. Recent Partnerships: Distribution by Type of Therapy
Table 14.21. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Table 14.22. Recent Partnerships: Distribution by Cell Processing Step
Table 14.23. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Table 14.24. Recent Partnerships: Distribution by Type of Partner
Table 14.25. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Table 14.26. Recent Partnerships: Most Active Players
Table 14.27. Recent Partnerships: Country-Wise Distribution
Table 14.28. Recent Partnerships: Intercontinental and Intracontinental Distribution
Table 14.29. Big Pharma Initiatives Summary
Table 14.30. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
Table 14.31. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Table 14.32. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Table 14.33. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
Table 14.34. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
Table 14.35. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
Table 14.36. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
Table 14.37. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
Table 14.38. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
Table 14.39. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
Table 14.40. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
Table 14.41. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
Table 14.42. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
Table 14.43. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Table 14.44. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
Table 14.45. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
Table 14.46. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
Table 14.47. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
Table 14.48. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Table 14.49. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
Table 14.50. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
Table 14.51. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
Table 14.52. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
Table 14.53. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. A*STAR's Institute of Molecular and Cell Biology
  3. AbbVie
  4. Accellix
  5. Acer Therapeutics
  6. Achilles Therapeutics
  7. Activartis Biotech
  8. Adaptimmune
  9. Adicet Bio
  10. Aduro Biotech
  11. Adva Biotechnology
  12. Advent Bioservices 
  13. AgenTus Therapeutics
  14. Aglaris
  15. AK (Suzhou) Biomedical
  16. Aldagen
  17. Allele Biotechnology & Pharmaceuticals
  18. Allergan
  19. Allife Medical Science and Technology
  20. Allogene Therapeutics
  21. Altor BioScience
  22. AmerCare
  23. Amgen
  24. Amphera
  25. Anhui Kedgene Biotechnology
  26. ANI Pharmaceuticals
  27. Anterogen
  28. apceth Biopharma
  29. Araymondlife
  30. ARBELE
  31. Argos Therapeutics
  32. Asahi Glass Company
  33. Aseptic Technologies
  34. Astellas Pharma
  35. Asterias Biotherapeutics
  36. Astraveus
  37. AstraZeneca
  38. Asymptote
  39. Atara Biotherapeutics
  40. Athersys
  41. Atlantic Bio GMP
  42. ATLATL Innovation Cluster
  43. Atreca
  44. Aurora Biopharma
  45. Autolus
  46. AVAX Technologies
  47. Basic Pharma
  48. Batavia Bioservices
  49. Bavarian Nordic
  50. Baxalta
  51. Baxter
  52. Bayer
  53. Beijing Biohealthcare Biotechnology
  54. Beijing Doing Biomedical
  55. Beijing Immunochina Medical Science & Technology
  56. Beijing Sanwater Biological Technology
  57. Beijing Tricision Biotherapeutics 
  58. Beike Biotechnology
  59. Bellicum Pharmaceuticals
  60. Bio Elpida
  61. BioAtla
  62. BioCardia
  63. Biogen
  64. Bioinova
  65. BioNTech Innovative Manufacturing Services
  66. Bio-Process Systems Alliance
  67. BioRestorative Therapies
  68. Biosafe
  69. Biotec Services International
  70. Bio-Techne
  71. bluebird bio
  72. Boehringer Ingelheim
  73. Bone Therapeutics
  74. BrainStorm Cell Therapeutics
  75. Brammer Bio
  76. Bristol Myers Squibb
  77. BTI
  78. Caladrius Biosciences
  79. CANCER-ID
  80. Capricor Therapeutics
  81. Captain T Cell
  82. CardioCell
  83. Carina Biotech
  84. CARsgen Therapeutics
  85. CAR-T (Shanghai) Biotechnology
  86. Cartherics
  87. Celgene
  88. Celixir
  89. Cell and Gene Therapy Catapult
  90. Cell Biotech
  91. Cell Genesys
  92. Cell Tech Pharmed
  93. Cell Therapies
  94. Cellectis
  95. CELLforCURE
  96. CellGenix
  97. Cellin Technologies
  98. Cellmed
  99. CellPraxis
  100. CellProtect Nordic Pharmaceuticals
  101. CellProthera
  102. Cellular Biomedicine Group
  103. Cellular Therapeutics
  104. Celularity
  105. Celyad
  106. Centre for Commercialization of Regenerative Medicine
  107. Chengdu MedGenCell
  108. CiMaas
  109. Cognate BioServices
  110. Cook MyoSite
  111. Cord Blood Registry
  112. Cordlife
  113. Corestem
  114. CRISPR Therapeutics
  115. CRMI
  116. Cryosite
  117. Cytiva
  118. Cytopeutics
  119. Cytori Therapeutics
  120. Cytosen Therapeutics
  121. Cytovac
  122. CyTuVax 
  123. Daiichi Sankyo
  124. Daikyo Seiko
  125. Danaher
  126. DanDrit Biotech
  127. DCPrime
  128. Delta-Vir
  129. DEMCON
  130. Dendreon
  131. DiscGenics
  132. Draper
  133. Eli Lilly
  134. Endocyte
  135. Esco Aster
  136. Esco VacciXcell
  137. Eureka Therapeutics
  138. Eutilex
  139. Ever Union Biotechnology 
  140. eXmoor Pharma Concepts
  141. EXUMA Biotechnology
  142. Fate Therapeutics
  143. Ferrer Internacional
  144. FIB Hospital Infantil Universitario Niño Jesús
  145. Fibrocell Technologies
  146. Five Prime Therapeutics
  147. Flaskworks
  148. FloDesign Sonics
  149. Formula Pharmaceuticals
  150. Fortress Biotech
  151. Fred Hutchinson Cancer Research Center
  152. Freeline
  153. Fresenius Kabi
  154. FUJIFILM Cellular Dynamics
  155. FUJIFILM Diosynth Biotechnologies
  156. Gadeta
  157. Gamida Cell
  158. GC Cell
  159. G-Con Manufacturing
  160. GE Healthcare
  161. GE Medical Systems Trade & Development (Shanghai)
  162. Genentech
  163. Genzyme
  164. GigaGen 
  165. Gilead Sciences
  166. GlaxoSmithKline
  167. Global Cell Med
  168. Glycostem Therapeutics
  169. GPB Scientific
  170. Gracell Biotechnologies
  171. Gradalis
  172. Green Cross
  173. GRI Bio
  174. Guangzhou Trinomab Biotech
  175. Haemonetics
  176. Heat Biologics
  177. Hebei Senlang Biotechnology
  178. Hemostemix
  179. HengRui YuanZheng Bio-Technology
  180. Histocell
  181. Histogenics
  182. Hitachi Chemical Advanced Therapeutics Solutions
  183. Holostem Terapieavanzate
  184. Human Life CORD Japan
  185. Hunan Zhaotai Yongren Biotech
  186. iCarTAB BioMed
  187. iCell Gene Therapeutics
  188. Immatics
  189. Immune Therapeutics
  190. Immunicum
  191. ImmunoCellular Therapeutics
  192. Immunocore
  193. Immunovative Therapies 
  194. IncoCell Tianjin
  195. Incysus
  196. Innovative Cellular Therapeutics
  197. Inovio Pharmaceuticals
  198. inRegen
  199. Intellia Therapeutics
  200. Intrexon
  201. Invetech
  202. Iovance Biotherapeutics
  203. ISTO Technologies
  204. Ivy Life Sciences
  205. Janssen
  206. Japan Tissue Engineering (J-TEC)
  207. Johns Hopkins University
  208. Johnson & Johnson
  209. Juno Therapeutics
  210. JW Biotechnology
  211. JW CreaGene
  212. KangStem Biotech
  213. Kawasaki Heavy Industries
  214. KBI Biopharma
  215. Kiromic
  216. Kite Pharma
  217. Konkuk University
  218. kSep Systems
  219. Kuur Therapeutics
  220. Legend Biotech
  221. Leucid Bio
  222. Lifecells
  223. Lion TCR
  224. Living Pharma
  225. Longeveron
  226. Lonza
  227. Lorem Cytori
  228. Lorem Vascular
  229. Marino Biotechnology
  230. Marker Therapeutics
  231. MaSTherCell
  232. Max Planck Institute for Dynamics of Complex Technical Systems
  233. MaxCyte
  234. MedCision
  235. Medeor Therapeutics
  236. Medigene
  237. MEDINET
  238. MEDIPOST
  239. MedVax Technologies
  240. Merck
  241. Merck Serono
  242. Mesoblast
  243. MicrofluidX
  244. Miltenyi Biotec
  245. Minovia Therapeutics
  246. MolecuVax
  247. MolMed
  248. Moraga Biotechnology
  249. Multimmune
  250. Mustang Bio 
  251. NantKwest
  252. Neopharm
  253. NewLink Genetics
  254. Nikon CeLL innovation
  255. Nkarta
  256. Noga Therapeutics
  257. Nohla Therapeutics
  258. Noile-Immune Biotech
  259. Northern Therapeutics
  260. Northwest Biotherapeutics
  261. Novadip Biosciences
  262. Novartis
  263. NovaRx
  264. Novella Clinical
  265. Novo Nordisk
  266. Octane Biotech
  267. OhioHealth
  268. OiDE BetaRevive
  269. Ompi
  270. Oncobiomed
  271. Opexa Therapeutics
  272. Orchard Therapeutics
  273. Orgenesis
  274. Ori Biotech
  275. Osiris Therapeutics
  276. OSPIN
  277. Oxford BioMedica
  278. Oxford MEStar
  279. Pall Corporation
  280. Parker Institute for Cancer Immunotherapy
  281. PDC*line Pharma
  282. PersonGen BioTherapeutics
  283. Pfizer
  284. PharmaBio
  285. PharmaCell
  286. Pharmicell
  287. Pinze Lifetechnology
  288. Pique Therapeutics
  289. Pluristem Therapeutics
  290. Poseida Therapeutics
  291. Praxis Pharmaceutical
  292. Precision BioSciences
  293. Pregene ShenZhen Biotechnology
  294. Immutep
  295. Promethera Biosciences
  296. Regeneris Medical
  297. Regeneron
  298. Regeneus
  299. ReNeuron
  300. RHEACELL
  301. Roche
  302. Roslin Cells
  303. Sangamo Therapeutics
  304. Sanofi
  305. Saronic Biotechnology
  306. Sartorius
  307. Sartorius Stedim Biotech
  308. SCHOTT
  309. Scinogy
  310. Scinus Cell Expansion
  311. Sclnow Biotechnology
  312. Seattle Genetics
  313. Seneca Biopharma
  314. Sentien Biotechnologies
  315. Servier
  316. Shanghai Bioray Laboratory
  317. Shanghai GeneChem
  318. Shanghai Houchao Biotechnology
  319. Shanghai iCELL Biotechnology
  320. Shanghai Longyao Biotechnology
  321. Shanghai Unicar-Therapy Bio-medicine Technology
  322. Sheba Medical Center
  323. Shenzhen BinDeBio
  324. Shenzhen Hornetcorn Biotechnology
  325. Shibuya
  326. Shionogi
  327. Shreedhar Instruments
  328. Singota Solutions
  329. Sinobioway Cell Therapy
  330. SMT Bio
  331. Sorrento Therapeutics
  332. SOTIO
  333. Southwest Research Institute
  334. SQZ Biotech
  335. Stafa Cellular Therapy
  336. Stanford School of Medicine
  337. Stem Cell Arabia
  338. STEMCELL Technologies
  339. Stemedica Cell Technologies
  340. Stempeutics Research
  341. Super-T Cell Cancer Company
  342. Surface Oncology
  343. Tactiva Therapeutics
  344. Taiwan Bio Therapeutics
  345. Takara Bio
  346. Takeda Pharmaceuticals
  347. TapImmune 
  348. Targazyme
  349. TC BioPharm
  350. TCR2 Therapeutics
  351. Tella
  352. Terumo BCT
  353. Tessa Therapeutics
  354. Teva Pharmaceutical Industries
  355. TheraCell Advanced Biotechnology
  356. Thermo Fisher Scientific
  357. ThermoGenesis
  358. Tianhe Stem Cell Biotechnologies
  359. TiGenix
  360. TILT Biotherapeutics
  361. Tissue Genesis
  362. Tmunity Therapeutics
  363. TNK Therapeutics
  364. TotipotentRX
  365. TRACT Therapeutics
  366. TrakCel
  367. TransCure BioServices
  368. Triumvira Immunologics
  369. TVAX Biomedical
  370. Shanghai Unicar Therapy Bio medicine Technology
  371. Universal Cells
  372. University of California, Davis
  373. University Of North Carolina Lineberger Comprehensive Cancer Center
  374. Unum Therapeutics
  375. US Stem Cell
  376. Vaccinogen
  377. Vanrx Pharmasystems
  378. Vericel
  379. ViroMed
  380. Viscofan BioEngineering
  381. VivaBioCell
  382. Volta Therapeutics
  383. Waisman Biomanufacturing
  384. WiSP Wissenschaftlicher Service Pharma
  385. Wuhan Sian Medical Technology
  386. WuXi AppTec
  387. Xcelthera
  388. Xellbiogene
  389. XEME Biopharma
  390. Yposkesi
  391. Zelluna Immunotherapy 
  392. Zenith Technologies
  393. Zimmer Biomet
  394. Ziopharm Oncology

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com